Induction of cytotoxic T lymphocytes against human cancer cell lines using dendritic cell-tumor cell hybrids generated by a newly developed electrofusion technique

International Journal of Oncology

Volumn 29, Issue 3, 2006, Pages 531-539

  Imura, Kenichiro ^a   Ueda, Yuji ^a   Hayashi, Takashi ^b   Itoh, Tsuyoshi ^a   Shimizu, Keiji ^a   Tamai, Hidemasa ^a   Yano, Yutaro ^a   Naito, Kei ^a   Kohara, Junji ^a   Nakane, Kazuki ^c   Matsuura, Yuko ^c   Takeda, Atsuko ^c   Takeda, Takahisa ^c   Kawai, Keiichi ^c   Yamagishi, Hisakazu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b Center for Cerebrovascular Disease   (Japan)

^c Inariyama Hospital   (Japan)

Author keywords

Cancer immunotherapy; Cytotoxic T lymphocyte; DC tumor hybrid; Dendritic cell; Electrofusion; Human cancer cell line

Indexed keywords

ANTINEOPLASTIC AGENT; GAMMA INTERFERON; INTERLEUKIN 12; TUMOR ANTIGEN;

ADENOCARCINOMA; ADULT; ARTICLE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL FUSION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; HYBRID CELL; IMMUNOLOGY; LUNG TUMOR; MALE; METABOLISM; PATHOLOGY; SQUAMOUS CELL CARCINOMA; STOMACH TUMOR;

ADENOCARCINOMA; ADULT; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CD8-POSITIVE T-LYMPHOCYTES; CELL FUSION; DENDRITIC CELLS; HUMANS; HYBRID CELLS; INTERFERON TYPE II; INTERLEUKIN-12; LUNG NEOPLASMS; MALE; STOMACH NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 33749347912     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.29.3.531     Document Type: Article

References (32)

1. Brossart P, Wirths S, Brugger W and Kanz L: Dendritic cells in cancer vaccines. Exp Hematol 29: 1247-1255, 2001.
2. Steinman R and Nussenzweig M: Dendritic cells; features and functions. Immunol Rev 53: 127-147, 1980.
3. Banchereau J, Brie F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B and Palucka K: Immunobiology of dendritic cells. Annu Rev Immunol 18: 767-811, 2000.
4. Schuler-Thurner B, Schultz SE, Berger GT, Weinlich G, Ebner S, Woerl P, Bender A, Feuerstein B, Fritsch OP, Romani N and Schuler G: Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 195: 1279-1288, 2002. (Pubitemid 34564330)
5. Brossart P, Wirths S, Stuhler G, Reichardt LV, Kanz L and Brugger W: Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96: 3102-3108, 2000.
6. Matsuyoshi H, Senju S, Hirata S, Yoshitake Y, Uemura Y and Nishimura Y: Enhanced priming of antigen-specific CTLs in vivo by embryonic stem cell-derived dendritic cells expressing chemokine along with antigenic protein; application to antitumor vaccination. J Immunol 172: 776-786, 2004. (Pubitemid 38113733)
7. Schmitz M, Diestelkoetter P, Weigle B, Schmachtenberg F, Stevanovic S, Ockert D, Rammensee HG and Rieber PE: Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res 60: 4845-4849, 2000.
8. Su Z, Dannull J, Heiser A, Yancey D, Pruitt S, Madden J, Coleman D, Niedzwiecki D, Gilboa E and Vieweg J: Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 63: 2127-2133, 2003. (Pubitemid 36538616)
9. Duane AM and Smita KN: RNA-transfected dendritic cells in cancer immunotherapy. J Clin Invest 106: 1065-1069, 2000.
10. Heiser A, Maurice AM, Yancey RD, Coleman MD, Dahm P and Vieweg J: Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res 61: 3388-3393, 2001. (Pubitemid 32695030)
11. Yu SJ, Liu G, Ying H, Yong HW, Black LK and Wheeler JC: Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64: 4973-4979, 2004. (Pubitemid 38924545)
12. Hus I, Rolinski J, Tabarkiewicz J, Wojas K, Bojarska-Junak A, Greiner J, Giannopoulos K, Dmoszynska A and Schmitt M: Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia. Leukemia 19: 1621-1627, 2005. (Pubitemid 43090407)
13. Stift A, Friedl J, Dubsky P, Bachleitner-Hofmann T, Schueller G, Zontsich T, Benkoe T, Radelbauer K, Brostjan C, Jakesz R and Gnant M: Dendritic cell-based vaccination in solid cancer. J Clin Oncol 21: 135-142, 2003.
14. Candido AK, Shimizu K, McLaughlin CJ, Kunkel R, Fuller AJ, Redman GB, Thomas KE, Nickoloff JB and Mule JJ: Local administration of dendritic cells inhibits established breast tumor growth; implications for apoptosis-inducing agents. Cancer Res 61: 228-236, 2001 (Pubitemid 32095722)
15. Zhou Y, Bosch ML and Salgaller ML: Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity. J Immunother 25: 289-303, 2002. (Pubitemid 34857284)
16. Laskov R, Kim JK and Asofsky R: Induction of amplified synthesis and secretion of IgM by fusion of murine B lymphoma with myeloma cells. Proc Natl Acad Sci USA 76: 915-919, 1979.
17. Hayashi T, Tanaka H, Tanaka J, Wang R, Averbook JB, Cohen AP and Shu S: Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion. Clin Immunol 104: 14-20, 2002. (Pubitemid 34856504)
18. Tanaka H, Shimizu K, Hayashi T and Shu S: Therapeutic immune response induced by electrofusion of dendritic and tumor cells. Cell Immunol 220: 1-12, 2002. (Pubitemid 36444494)
19. Kuriyama H, Shimizu K, Lee W, Kjaergaard J, Parkhurst MR, Cohen PA and Shu S: Therapeutic vaccine generated by electrofusion of dendritic cells and tumour cells. Dev Biol 116: 169-178, 2004. (Pubitemid 38091551)
20. Shimizu K, Kuriyama H, Kjaergaard J, Lee W, Tanaka H and Shu S: Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. J Immunother 27: 265-272, 2004. (Pubitemid 38833322)
21. Lee TW, Shimizu K, Kuriyama H, Tanaka H, Kjaergaard J and Shu S: Tumor-dendritic cell fusion as a basis for cancer immunotherapy. Otolaryngol Head Neck Surg 132: 755-764, 2005.
22. Haenssle AH, Krause WS, Emmert S, Zutt M, Kretschmer L, Schmidberger H, Andreesen R and Soruri A: Hybrid cell vaccination in metastatic melanoma clinical and immunologic results of a phase I/II study. J Immunother 27: 147-155, 2004.
23. Trefzer U, Herberth G, Wohlan K, Milling A, Thiemann M, Sharav T, Sparbier K, Sterry W and Walden P: Tumor-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results. Vaccine 23: 2367-2373, 2005.
24. Kao YJ, Gong Y, Chen MC, Zheng DQ and Chen JJ: Tumor-derived TGFβ reduces the efficacy of dendritic cell/tumor fusion vaccine. J Immunol 170: 3806-3811, 2003.
25. Lee AW, Truong T, Bickham K, Fonteneau JF, Larsson M, Da SI, Somersan S, Thomas EK and Bhardwaj N: A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. Vaccine 20: A8-A22, 2002.
26. + T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor. J Immunol 164: 3902-3912, 2000.
27. Uherek C, Tonn T, Uherek B, Becker S, Schnierle B, Klingemann HG and Wels W: Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 100: 1265-1273, 2002.
28. Gong J, Nikrui N, Chen D, Koido S, Wu Z, Tanaka Y, Cannistra S, Avigan D and Kufe DJ: Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. Immunology 165: 1705-1711, 2003.
29. Kikuchi T, Akasaki Y, Irie M, Homma S, Abe T and Ohno T: Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 50: 337-340, 2001.
30. Krause SW, Neumann C, Soruri A, Mayer S, Peters JH and Andreesen R: The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells. J Immunother 25: 421-428, 2002.
31. Trevor TK, Cover C, Ruiz WY, Akporiaye TE, Hersh ME, Landais D, Taylor RR, King DA and Walters ER: Generation of dendritic cell-tumor cell hybrids by electrofusion for clinical vaccine application. Cancer Immunol Immunother 53: 705-714, 2004.
32. Tatsumi T, Takehara T, Kanto T, Miyagi T, Kuzushita N, Sugimoto Y, Jinushi M, Kasahara A, Sasaki Y, Hori M and Hayashi N: Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma. Cancer Res 61: 7563-7567, 2001.